Publication | Closed Access

Cost-Effectiveness Model for Chemoimmunotherapy Options in Patients with Previously Untreated Chronic Lymphocytic Leukemia Unsuitable for Full-Dose Fludarabine-Based Therapy

Chemoimmunotherapy OptionsHematological MalignancyMedicineOutcomes ResearchFull-dose Fludarabine-based TherapyPharmacotherapyCost EffectivenessImmunotherapyOncologyRadiation OncologyCost-effectiveness ModelTreatment Plan Evaluation